LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.
Read More
LifeArc, the UK medical research charity formerly known as MRC Technology, is investing £500 million over the next five years to underpin its aims of advancing innovations in antimicrobials, neuroscience, personalised oncology and respiratory medicine.
Read More
UK medical research charity MRC Technology has licensed an antibody to Newsummit Biopharma, a leading China-based drug development process solutions provider, for development of a novel therapeutic for treatment of Hepatitis C virus infection.
Read More
AstraZeneca, MRC Technology and Asthma UK and the British Lung Foundation have joined forces to investigate the link between epigenetics and respiratory disease.
Read More
Medical research charity MRC Technology and AstraZeneca are partnering to launch an initiative to find new epigenetic drug targets in respiratory disease.
Read More
